Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IPA
DateTimeSourceHeadlineSymbolCompany
23/01/202506:19Business WireIPA (ImmunoPrecise Antibodies), pionnier des thérapies GLP-1 conçues par l'IA : Un nouveau chapitre potentiel en matière de traitement du diabèteNASDAQ:IPAImmunoPrecise Antibodies Ltd
23/01/202502:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
22/01/202523:02Business WireIPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes TreatmentNASDAQ:IPAImmunoPrecise Antibodies Ltd
18/01/202513:25Business WireImmunoPrecise Antibodies redéfinit sa stratégie de pipeline en faisant appel à l'IA et à l'innovation basée sur les principes premiers pour la découverte de médicamentsNASDAQ:IPAImmunoPrecise Antibodies Ltd
18/01/202503:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
18/01/202500:01Business WireImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles InnovationNASDAQ:IPAImmunoPrecise Antibodies Ltd
04/01/202502:20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
01/01/202523:44Business WireL'IPA annonce la démission de sa directrice financièreNASDAQ:IPAImmunoPrecise Antibodies Ltd
01/01/202511:56Business WireIPA Announces Resignation of Chief Financial OfficerNASDAQ:IPAImmunoPrecise Antibodies Ltd
24/12/202404:02Business WireImmunoPrecise Antibodies (IPA) démontre une solide confiance du marché avec des achats d'actions par des membres de la directionNASDAQ:IPAImmunoPrecise Antibodies Ltd
24/12/202401:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
24/12/202400:30Business WireImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share PurchasesNASDAQ:IPAImmunoPrecise Antibodies Ltd
20/12/202404:56Business WirePrésentation de l'IPA à la Microcap Conference 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
20/12/202400:00Business WireIPA to Present at The Microcap Conference 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/12/202422:34Business WireImmunoPrecise Antibodies (IPA) publie ses résultats financiers et les faits saillants de ses activités du deuxième trimestre de l’exercice 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/12/202400:37Edgar (US Regulatory)Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/12/202400:36Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/12/202400:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/12/202400:30Business WireImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
05/12/202422:23Business WireL'IPA participera à la prochaine conférence de découverte en tête-à-tête d'investisseurs organisée par The Benchmark CompanyNASDAQ:IPAImmunoPrecise Antibodies Ltd
05/12/202400:00Business WireIPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceNASDAQ:IPAImmunoPrecise Antibodies Ltd
04/12/202415:08Business WireL'IPA publiera ses résultats financiers et les faits importants de son activité récente pour le deuxième trimestre de l'exercice 2025 le 10 décembre 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
04/12/202400:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
04/12/202400:30Business WireIPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
15/11/202407:13Business WireUne percée commerciale de 20 milliards de dollars : l'IPA est pionnière dans le développement d'anticorps à fort impact pour les thérapies anticancéreuses ADC de nouvelle générationNASDAQ:IPAImmunoPrecise Antibodies Ltd
14/11/202401:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
14/11/202401:00Business Wire$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer TherapiesNASDAQ:IPAImmunoPrecise Antibodies Ltd
05/11/202417:53Business WireImmunoPrecise annonce son TECHDAY, un événement dédié à l'innovation de pointe en matière d'IA et de produits biologiquesNASDAQ:IPAImmunoPrecise Antibodies Ltd
05/11/202400:54Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
05/11/202400:01Business WireImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics InnovationNASDAQ:IPAImmunoPrecise Antibodies Ltd
 Showing the most relevant articles for your search:NASDAQ:IPA

Your Recent History

Delayed Upgrade Clock